Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. - Wikidata - awgldk - TriplyDB

Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis.

Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis.

http://www.wikidata.org/entity/Q44283320

about

The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis Targeting the redox balance in inflammatory skin conditions Polymorphisms in SPARC and coal workers' pneumoconiosis risk in a Chinese population Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules.DNA damage responses and oxidative stress in dyskeratosis congenita.Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis.Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.Efficacy study of edaravone and acetylcysteine towards bleomycin-induced rat pulmonary fibrosis Efficacy of antioxidant in idiopathic pulmonary fibrosis: A systematic review and meta-analysis Recommendations for the management of idiopathic pulmonary fibrosis in South Africa: a position statement of the South African Thoracic Society A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK Year in review 2012: acute lung injury, interstitial lung diseases, sleep and physiology.Ambroxol hydrochloride in the management of idiopathic pulmonary fibrosis: Clinical trials are the need of the hour.Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group.Secreted protein acidic and rich in cysteine (SPARC) is upregulated by transforming growth factor (TGF)-β and is required for TGF-β-induced hydrogen peroxide production in fibroblasts Effects of N-acetyl-L-cysteine on the membrane vesicle release and growth of respiratory pathogens.Analysis of blood neutrophil elastase, glutathione levels and pathological findings in postoperative acute exacerbation of idiopathic pulmonary fibrosis associated with lung cancer: Two case reports.Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.Recent advances in idiopathic pulmonary fibrosis Nuclear Thioredoxin-1 Overexpression Attenuates Alcohol-Mediated Nrf2 Signaling and Lung Fibrosis.Chronic alcohol ingestion primes the lung for bleomycin-induced fibrosis in mice.Antioxidants and NOX1/NOX4 inhibition blocks TGFβ1-induced CCN2 and α-SMA expression in dermal and gingival fibroblasts.The Relationship Between Airway Antioxidant Levels, Alcohol Use Disorders, and Cigarette Smoking.The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis.Combination pirfenidone and inhaled N-acetylcysteine therapy for IPF: does it take these two to tango?An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.Safety and efficacy of N-acetyl-cysteine for prophylaxis of ventilator-associated pneumonia: a randomized, double blind, placebo-controlled clinical trial.

P2860

Q21195756-C10C5D22-89EC-45BC-B729-48B51FE6D894 Q26750418-19C88926-F777-4075-86A8-0589A54F2768 Q26771309-AABF3E9F-9ED3-4F83-97FB-3954127C6C5E Q26849378-C50CB562-BFCC-40A5-AF40-1C19B64DDF7F Q27023252-A4192A02-02EC-4124-AB30-66B4F59AC2ED Q28392458-968C3746-C828-486F-BC6B-4D1C1EAAF5A8 Q33799573-30262B4E-BE7A-4F4E-BE77-C885A8A2D5AF Q35016987-999F6475-4E78-4256-89BF-6AAEC5F34A51 Q35618605-5B1669D1-C0EF-414D-8358-DDC47F8A4C3D Q35914125-DA60B07B-7FCB-4E49-8C34-EAB8A68048AE Q35958898-5069E7FC-14EA-4E0B-8BAB-61C43E937AFA Q36252121-CB3A55AA-0064-4A76-8B66-9E10CD465164 Q37581185-A3B528FA-6A07-4EAE-BAB7-FC353D252F0E Q37710138-D1846A15-135B-4DE5-9155-1AA10CA4FF31 Q38075587-98A10DA8-8DE6-4AFF-AB3D-8378ED8F6E34 Q38368368-CAD90A34-6382-4802-8883-5CF4CFBE448C Q38833606-A094F45C-83DA-4E00-A354-5F6E24E05E51 Q39013034-12A30783-2D81-4233-B908-94F5F81F046A Q39372019-894A3126-E844-4B17-9141-4E8F37BBF2A8 Q40237147-2D5BEE0A-C5AC-4C65-83AC-A34E49E8ACEE Q41193888-3A5828FF-3443-4CDF-A4C6-E7F7DBCF3DC8 Q41499477-C939F267-14FB-44A8-AAA7-6C08B1ACF289 Q41772378-96C22EC4-DA82-46F5-9F6C-79DDF8482C85 Q42092411-B8A00191-3230-4688-A452-82A38B2B000B Q42781291-2C5D5242-05CD-4006-9354-864389FA1886 Q43434250-F1E9C8EB-6390-40A0-A66A-C54B0528EEA3 Q46489543-C42A61C3-BD1A-445B-BE04-B175D2F5993E Q48096415-F66780E7-62D0-4C24-9407-7F0B8FC7B746 Q48116222-011738DC-3AEE-4531-8631-1025D936E5BC Q51612566-2D417CFF-9459-4BE5-87E2-95C79A689C94 Q54209289-5913C8F6-EE1C-4A44-A648-B33C5FEADBEC

P2860

Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis.

http://www.wikidata.org/entity/Q44283320

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Efficacy of inhaled N-acetylcy ...... idiopathic pulmonary fibrosis.

@en

Efficacy of inhaled N-acetylcy ...... idiopathic pulmonary fibrosis.

@nl

type

label

Efficacy of inhaled N-acetylcy ...... idiopathic pulmonary fibrosis.

@en

Efficacy of inhaled N-acetylcy ...... idiopathic pulmonary fibrosis.

@nl

prefLabel

Efficacy of inhaled N-acetylcy ...... idiopathic pulmonary fibrosis.

@en

Efficacy of inhaled N-acetylcy ...... idiopathic pulmonary fibrosis.

@nl

P1433

Q44283320-ABC91FCC-EE11-4BF3-AAC7-FECB56BB8CEB

P1476

Q44283320-7A3AF248-1D65-4F72-8EDA-3E3E306263C5

P2093

Q44283320-11673883-64DA-4579-B5F6-B37516679D92

Q44283320-1470595A-1929-4F64-B7C5-2DCD366EA6CB

Q44283320-46A088D6-688F-4F2C-9EF8-7EEFA47F1620

Q44283320-575420EB-D5E7-4AC2-A2F0-E9BC767FBEB1

Q44283320-62EFBBAA-0E8D-483C-A9B7-40102E3408F5

Q44283320-7018200D-B6F3-4116-BF4E-1DC18717CFBD

Q44283320-7AB24BEF-D80A-4637-995B-4E12B35CA279

Q44283320-90B8C085-0D03-46FE-9C93-E23D0FFB0A09

Q44283320-C8D84834-18B1-4E6B-8147-5654A0C3E2DF

Q44283320-DA412902-BCAE-4DD2-8875-38D7770938FA

P2860

Q44283320-0346B711-E41D-41AE-A17D-CEBCE2141F7E

Q44283320-0EA94F87-E6E6-49CC-8D8A-CC7C87DD2BC7

Q44283320-1199A7D3-38B3-41F6-90E6-7CE80AF5225C

Q44283320-1A8467D3-550E-4ABA-B63C-BD630D3E97F5

Q44283320-3A1662F8-0C1C-4C94-B0C5-20E083907130

Q44283320-42CDF362-97CE-45DE-9968-1CF588FA4CD9

Q44283320-79F388E2-C3F0-4F16-88F3-82DAEB8CB70E

Q44283320-7BE94707-780B-426F-A4E2-FBD9F1E85A26

Q44283320-814D1E5F-7B2F-43AC-AF1B-34049902987E

Q44283320-96CD533A-061D-447F-BAE1-2CA4450171D9

P304

Q44283320-04CD9B5F-80D3-42F4-B8A0-7377E62B3CD5

P31

Q44283320-77CEC5F1-EDAA-4753-A18C-14EF0576C7D5

P356

Q44283320-AADF3CA5-947A-46AF-A912-E2F7E14B7817

P433

Q44283320-F83A1863-9065-46F0-BD78-D967EDF779FD

P478

Q44283320-1AC3021B-B34C-4F99-9A4C-BAC1B38C15CA

P577

Q44283320-BD062B3A-A1B9-4BEC-8E88-7CA4ACF805EC

P5875

Q44283320-DD864711-A586-4C3D-97E9-6E00EF264309

P698

Q44283320-59EE409B-2D7C-475C-B1D3-3B85BF81DCE1

P921

Q44283320-6211634E-C07F-49E7-B30F-819CC77B7DD9

P356

J.1440-1843.2012.02132.X

P1433

P1476

Efficacy of inhaled N-acetylcy ...... idiopathic pulmonary fibrosis.

@en

P2093

Arata Azuma

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Taniguchi

http://www.w3.org/2001/XMLSchema#string

Japan NAC Clinical Study Group

http://www.w3.org/2001/XMLSchema#string

Koichiro Nakata

http://www.w3.org/2001/XMLSchema#string

Kunihiko Yoshimura

http://www.w3.org/2001/XMLSchema#string

Masahiro Takeuchi

http://www.w3.org/2001/XMLSchema#string

Sakae Homma

http://www.w3.org/2001/XMLSchema#string

Shoji Kudoh

http://www.w3.org/2001/XMLSchema#string

Takashi Ogura

http://www.w3.org/2001/XMLSchema#string

Yoshiro Mochiduki

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Soci

High-dose acetylcysteine in idiopathic pulmonary fibrosis

Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Molecular mechanisms of N-acetylcysteine actions.

Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue.

Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test.

Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study.

A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis.

P304

467-477

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1440-1843.2012.02132.X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221759189

http://www.w3.org/2001/XMLSchema#string

P698

22257422

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis